Cytokeratin and CD30 expression in dysgerminoma

被引:18
|
作者
Cossu-Rocca, Paolo
Jones, Timothy D.
Roth, Lawrence M.
Eble, John N.
Zheng, Wenxin
Karim, Fadi W. Abdul
Cheng, Liang
机构
[1] Indiana Univ, Med Ctr, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA
[2] Univ Sassari, Dipartimento Patol, I-07100 Sassari, Italy
[3] Yale Univ, Dept Pathol, New Haven, CT 06520 USA
[4] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
关键词
ovarian neoplasia; germ cell tumors; dysgerminoma; immunohistochemistry; E-cadherin; CD30; histogenesis;
D O I
10.1016/j.humpath.2006.02.018
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Dysgerminoma is a malignant germ cell tumor of the ovary that shares morphological, immunophenotypic, and genetic features with its testicular counterpart, seminoma. Recent evidence supports the hypothesis that seminoma can differentiate into non-seminomatous germ cell tumor types. The progression of these tumors can be measured by their acquisition of the potential to express cytokeratin intermediate filaments, a characteristic specific to epithelial differentiation. Although testicular seminomas have been widely investigated, little is known about cytokeratin or E-cadherin expression in dysgerminomas. We investigated 26 formalin-fixed, paraffin-embedded ovarian dysgenninomas with immunohistochemical stains for CAM5.2, AE1/AE3, epithelial membrane antigen, cytokeratin 7, cytokeratin 20, high-molecular-weight keratin, and E-cadherin. In addition, we investigated the CD30 and vimentin immunoreactivity of these tumors. Immunoreactivity for CAM5.2 and for AE1/AE3 was present in more than 10% of neoplastic cells in 5 (19.2%) of 26 cases and in 2 (7.7%) of 26 cases, respectively. Cytokeratin 7 showed only focal positivity and never showed positive staining in greater than 10% of dysgerminoma cells. E-cadherin staining was positive in 2 cases showing weak membranous immunostaining in more than 10% of cells. Vimentin immunoreactivity was observed in only 2 dysgerminomas, both of which had less than 10% of the neoplastic cells staining. Cytokeratin 20, epithelial membrane antigen, high-molecular-weight keratin, and CD30 were consistently negative in all cases. Our study demonstrates that cytokeratin expression in dysgerminomas is not unusual and is consistent with the hypothesis that dysgerminomas have the capacity to differentiate along epithelial lines. Furthermore, the immunohistochemical staining patterns for cytokeratins, E-cadherin, and CD30 in dysgerminomas need to be considered when assessing differential diagnoses in difficult cases of primary ovarian tumors. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1015 / 1021
页数:7
相关论文
共 50 条
  • [31] Expression of CD30 and CD30 ligand in cultured cell lines from human germ-cell tumors
    Pera, MF
    Bennett, W
    Cerretti, DP
    LABORATORY INVESTIGATION, 1997, 76 (04) : 497 - 504
  • [32] CD30 antigen expression is involved in celiac disease
    Periolo, Natalia
    Guillen, Laura
    Barboza, Marcos
    Niveloni, Sonia
    Maurino, Eduardo
    Bai, Julio C.
    Chernavsky, Alejandra C.
    GASTROENTEROLOGY, 2008, 134 (04) : A520 - A520
  • [33] CD30 expression and survival in posttransplant lymphoproliferative disorders
    Kinch, Amelie
    Amini, Rose-Marie
    Hollander, Peter
    Molin, Daniel
    Sundstrom, Christer
    Enblad, Gunilla
    ACTA ONCOLOGICA, 2020, 59 (06) : 673 - 680
  • [34] Anaplastic large cell lymphoma, ALK1 (-), CD30 (+) with aberrant immunohistochemical expression of EMA and cytokeratin: a case report
    Mitkov, D.
    Vlahova, A.
    Dikov, T.
    Petrova, E.
    Christova, S.
    Mekjanov, M.
    Praznikova, T.
    Shemelekova, L.
    VIRCHOWS ARCHIV, 2014, 465 : S267 - S267
  • [35] Immunoexpression of CD30 and CD30 ligand in deciduas from spontaneous abortions
    Trovato, M
    Grosso, M
    Vitarelli, E
    Le Donne, M
    Barresi, V
    Trimarchi, F
    Barresi, G
    EUROPEAN JOURNAL OF HISTOCHEMISTRY, 2005, 49 (03): : 285 - 290
  • [36] Concordance Study of CD30 Expression Detected By Multiple Immunohistochemistry Assays and Ventana CD30 Assay in Chinese Lymphoma Patients
    Jiang, Xiang-Nan
    Shi, Yang
    Li, Xiao-Qiu
    BLOOD, 2021, 138
  • [37] CD30 Expression in Post-Transplant Lymphoproliferative Disorders
    Hartley, Christopher
    Hintzke, Maria
    Vaughan, James
    Hosking, Paul
    Harrington, Alexandra
    Kroft, Steven
    Olteanu, Horatiu
    MODERN PATHOLOGY, 2015, 28 : 349A - 349A
  • [38] CD30 expression in cutaneous B-cell lymphomas
    Afolayan-Oloye, Olabisi
    Zhao, Lili
    Tejasvi, Trilokraj
    Chan, May P.
    Harms, Paul W.
    Fullen, Douglas R.
    Wilcox, Ryan A.
    Hristov, Alexandra C.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2023, 50 (09) : 819 - 827
  • [39] CD30 Expression Does Not Predict Response To Brentuximab Vedotin
    Xu, Mina
    Katz, Samuel
    MODERN PATHOLOGY, 2015, 28 : 389A - 389A
  • [40] Expression of CD30 as a biomarker to predict response to brentuximab vedotin
    Xu, Mina L.
    Acevedo-Gadea, Carlos
    Seropian, Stuart
    Katz, Samuel G.
    HISTOPATHOLOGY, 2016, 69 (01) : 155 - 158